---
title: "HEARTBEAM INC C/WTS 31/10/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.18"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240056776.md"
datetime: "2025-05-13T20:05:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240056776.md)
  - [en](https://longbridge.com/en/news/240056776.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240056776.md)
---

# HEARTBEAM INC C/WTS 31/10/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.18

EPS: As of FY2025 Q1, the actual value is USD -0.18.

EBIT: As of FY2025 Q1, the actual value is USD -5.504 M.

### Segment Revenue

HeartBeam, Inc. operates as one segment, focusing on the development and commercialization of ambulatory ECG solutions.

### Operational Metrics

-   **Net Loss**: The net loss for the three months ended March 31, 2025, was $5.484 million, compared to $4.606 million for the same period in 2024, representing a 19% increase.
-   **Operating Expenses**: Total operating expenses increased by 15% from $4.784 million in 2024 to $5.504 million in 2025.
-   **General and Administrative Expenses**: Decreased by 15% to $2.012 million in 2025 from $2.356 million in 2024.
-   **Research and Development Expenses**: Increased by 44% to $3.492 million in 2025 from $2.428 million in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: $4.477 million for the three months ended March 31, 2025, compared to $3.463 million in 2024.
-   **Net Cash Used in Investing Activities**: $3.760 million in 2025, primarily due to the purchase of short-term investments.
-   **Net Cash Provided by Financing Activities**: $10.250 million in 2025, primarily from net proceeds from the sale of common stock.

### Unique Metrics

-   **Stock-Based Compensation Expense**: Total stock-based compensation expense was $1.109 million for the three months ended March 31, 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: HeartBeam plans to continue its efforts with commercial readiness activities in anticipation of a commercial launch following FDA clearance for its 12L synthesis software.
-   **Strategic Collaboration**: HeartBeam announced a strategic collaboration with AccurKardia to enhance its commercial offering for arrhythmia assessment, aiming to expedite product development efforts and reduce costs and timelines.
-   **AI Program**: The company is actively developing AI algorithms to provide additional value to patients and physicians, leveraging approximately one million standard 12L ECGs acquired from various sources.

### Related Stocks

- [BEATW.US](https://longbridge.com/en/quote/BEATW.US.md)

## Related News & Research

- [Oil drops on lower demand forecasts despite deadlock in US-Iran talks](https://longbridge.com/en/news/295727368.md)
- [Novo CEO says obesity market won't be winner-take-all battle with Lilly](https://longbridge.com/en/news/295777893.md)
- [Elon Musk's Tesla Weighs $10.1 Billion Solar Plant, Chamath Palihapitiya Calls It a Bet on Nuclear: Here's Why](https://longbridge.com/en/news/295754346.md)
- [CoreWeave and Nebius Group Deliver Earnings Shocker. Here's What It Signals About the Future of AI.](https://longbridge.com/en/news/295703122.md)
- [Dan Ives Says CoreWeave, Cisco Earnings ‘Pieces of the Puzzle’ for AI Trade: ‘Get the Popcorn Out’](https://longbridge.com/en/news/295693267.md)